Last reviewed · How we verify
DA-5212
DA-5212 is a selective inhibitor of phosphodiesterase 5 (PDE5) that enhances nitric oxide signaling to improve blood flow and tissue perfusion.
DA-5212 is a selective inhibitor of phosphodiesterase 5 (PDE5) that enhances nitric oxide signaling to improve blood flow and tissue perfusion. Used for Diabetic foot ulcers, Chronic wounds and tissue regeneration.
At a glance
| Generic name | DA-5212 |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | PDE5 inhibitor |
| Target | PDE5 (phosphodiesterase 5) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE5, DA-5212 increases cyclic GMP levels in vascular smooth muscle, leading to vasodilation and improved microcirculation. This mechanism is intended to enhance tissue oxygenation and promote healing in conditions characterized by impaired blood flow or ischemic injury.
Approved indications
- Diabetic foot ulcers
- Chronic wounds and tissue regeneration
Common side effects
- Headache
- Flushing
- Dyspepsia
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-5212 CI brief — competitive landscape report
- DA-5212 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI